These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21240150)

  • 41. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique.
    Hasan S; Buckley P
    Am J Psychiatry; 1998 Aug; 155(8):1113-6. PubMed ID: 9699705
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Neuroleptic malignant syndrome and atypical antipsychotics: a brief review].
    Khaldi S; Kornreich C; Choubani Z; Gourevitch R
    Encephale; 2008 Dec; 34(6):618-24. PubMed ID: 19081460
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India.
    Pallava A; Chadda RK; Sood M; Lakshmy R
    Nord J Psychiatry; 2012 Jun; 66(3):215-21. PubMed ID: 22017264
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolic syndrome in schizophrenia - who is more to blame: FGA polypharmacy or clozapine monotherapy?
    Softic R; Sutovic A; Avdibegovic E; Osmanović E; Bećirović E; Hajdukov MM
    Psychiatr Danub; 2015 Dec; 27(4):378-84. PubMed ID: 26609650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. What evidence is there to show which antipsychotics are more diabetogenic than others?
    Jesus C; Jesus I; Agius M
    Psychiatr Danub; 2015 Sep; 27 Suppl 1():S423-8. PubMed ID: 26417808
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics.
    Liou YJ; Bai YM; Lin E; Chen JY; Chen TT; Hong CJ; Tsai SJ
    Pharmacogenomics J; 2012 Feb; 12(1):54-61. PubMed ID: 20877301
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics.
    Krane-Gartiser K; Breum L; Glümrr C; Linneberg A; Madsen M; Køster A; Jepsen PW; Fink-Jensen A
    Nord J Psychiatry; 2011 Oct; 65(5):345-52. PubMed ID: 21428861
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association between SCAP and SREBF1 gene polymorphisms and metabolic syndrome in schizophrenia patients treated with atypical antipsychotics.
    Yang L; Chen J; Li Y; Wang Y; Liang S; Shi Y; Shi S; Xu Y
    World J Biol Psychiatry; 2016 Sep; 17(6):467-74. PubMed ID: 26982812
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metabolic syndrome and its relation to antipsychotic polypharmacy in schizophrenia, schizoaffective and bipolar disorders.
    Abdel Aziz K; Mohd Ahmed H; Stip E; Aly El-Gabry D
    Int Clin Psychopharmacol; 2024 Jul; 39(4):257-266. PubMed ID: 38381917
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points.
    McMillan SS; Jacobs S; Wilson L; Theodoros T; Robinson G; Anderson C; Mihala G; Wheeler AJ
    BMC Psychiatry; 2017 Apr; 17(1):139. PubMed ID: 28407747
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diabetes resolution following discontinuation of a second-generation antipsychotic.
    Strassnig M; Awerbuck J; Ganguli R
    Clin Schizophr Relat Psychoses; 2013 Jan; 6(4):202-3. PubMed ID: 23302450
    [No Abstract]   [Full Text] [Related]  

  • 52. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil.
    Teixeira PJ; Rocha FL
    Braz J Psychiatry; 2007 Dec; 29(4):330-6. PubMed ID: 18200397
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database.
    Sicras-Mainar A; Blanca-Tamayo M; Rejas-Gutiérrez J; Navarro-Artieda R
    Eur Psychiatry; 2008 Mar; 23(2):100-8. PubMed ID: 17904825
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metabolic syndrome and psychiatrists' choice of follow-up interventions in patients treated with atypical antipsychotics in Denmark and Sweden.
    Larsen JT; Fagerquist M; Holdrup M; Christensen B; Sigalin C; Nilsson PM
    Nord J Psychiatry; 2011 Feb; 65(1):40-6. PubMed ID: 20482460
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Altered metabolic parameters in association with antipsychotic medication use in diabetes: A population based case-control study.
    Wake DJ; Broughton P; Perera SM; MacIntyre DJ; Leese GP
    Psychoneuroendocrinology; 2016 Apr; 66():214-20. PubMed ID: 26849203
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factors in antipsychotic drug selection: tolerability considerations.
    Nasrallah HA
    CNS Spectr; 2003 Nov; 8(11 Suppl 2):23-5. PubMed ID: 14978455
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Monitoring and management of metabolic risk factors in outpatients taking antipsychotic drugs: a controlled study.
    Jennex A; Gardner DM
    Can J Psychiatry; 2008 Jan; 53(1):34-42. PubMed ID: 18286870
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metabolic monitoring and management among clozapine users.
    Tso G; Kumar P; Jayasooriya T; Kisely S; Siskind D
    Australas Psychiatry; 2017 Feb; 25(1):48-52. PubMed ID: 27590080
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Antipsychotics].
    Yamada H; Hashimoto R
    Brain Nerve; 2023 May; 75(5):579-584. PubMed ID: 37194535
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetics of second-generation antipsychotic and mood stabilizer-induced weight gain in bipolar disorder: common and specific effects of key regulators of fat-mass homoeostasis genes.
    Creta E; Fabbri C; Serretti A
    Pharmacogenet Genomics; 2015 Jul; 25(7):354-62. PubMed ID: 25946404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.